SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biomea Fusion, Inc. - BMEA

The investigation concerns whether Biomea and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On June 6, 2024, Biomea issued a press release "announc[ing] that the Company has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVA ...